ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA-Reference-Cited by-同舟云学术

ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA

Published:2016-11-01 Issue:suppl_6 Volume:18 Page:vi17-vi18
ISSN:1522-8517
Container-title:Neuro-Oncology
language:en
Short-container-title:

Author:

Weller Michael,Butowski Nicholas,Tran David,Recht Lawrence,Lim Michael,Hirte Hal,Ashby Lynn,Mechtler Lazlo,Goldlust Samuel,Iwamoto Fabio,Drappatz Jan,O’Rourke Donald,Wong Mark,Finocchiaro Gaetano,Perry James,Wick Wolfgang,He Yi,Davis Thomas,Stupp Roger,Sampson John

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Neurology (clinical),Oncology

Link

http://academic.oup.com/neuro-oncology/article-pdf/18/suppl_6/vi17/9645269/now212.068.pdf

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent in vitro models and tissue engineering strategies to study glioblastoma;Biotech Studies;2024-06-30

2. Clinical, qualitative imaging biomarkers, and tumor oxygenation imaging biomarkers for differentiation of midline-located IDH wild-type glioblastomas and H3 K27-altered diffuse midline gliomas in adults;European Journal of Radiology;2024-04

3. Prognosis and clinical features analysis of EMT-related signature and tumor Immune microenvironment in glioma;Journal of Medical Biochemistry;2023

4. Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment;Frontiers in Medicine;2022-09-14

5. Current and promising treatment strategies in glioma;Reviews in the Neurosciences;2022-09-06